base.gw_DRG07eap
NEWS & MEETINGS
Insight
Through its professional digital service capabilities, Hippocrates has helped many life sciences companies achieve remarkable success in meeting regulatory requirements, ensuring compliance and improving operational efficiency. We will release the latest training courses and exhibition information as soon as possible. Please visit the official homepage of "Hippocrates" on media such as "WeChat Official Account, Weibo, Zhihu, Bopu, Douyin, Baijiahao, Sohu" to obtain our latest information and live courses.
07/22
July 22 ,2024

【公开课报名】医药数字化系列第5期:监管驱动的制药企业数字化治理和赋能体系建设

Co-hosted by Kaisi Club, Hippcrates Yingu Information Technology and other organizations, the 5th session of the Online Pharmaceutical Digitalization Series Open Class will be broadcast live online from 19:30 to 21:00 on May 7. This session invites Dr. Xiao Liang, Founder & CEO of Singdi, to deliver a keynote speech titled Regulation-Driven Digital Governance and Empowerment System Construction for Pharmaceutical Enterprises. Registration is open to all participants! (Details below)


I. Guest Profile

Dr. Xiao Liang

Founder & CEO, Hippcrates


Dr. Xiao holds a Master of Medicine from Xiangya School of Medicine, Central South University, and a Doctor of Pharmacology from Shanghai Institute of Materia Medica, Chinese Academy of Sciences. He is a Senior Engineer and the Principal Investigator of the National 12th Five-Year Plan Major New Drug Creation Project under the Ministry of Science and Technology.


As the first inventor, he has filed 5 patents and published more than 20 research papers, over 10 of which are English articles featured in SCI international journals.

After completing his doctoral studies, he worked as a Senior Researcher at Hengrui Medicine Shanghai R&D Center and later served as Head of the Clinical Department at Shanghai Huilun Life Science Co., Ltd. He oversaw preclinical development and clinical trial management for dozens of innovative drugs, including DPP4 inhibitors, c-Met inhibitors, PARP inhibitors, Apatinib and Flumatinib.

In June 2013, he co-founded Taimei Medical Technology Co., Ltd., where he served as General Manager and Chief Scientific Officer. The company focuses on digital operation platforms for clinical trials.


In August 2019, he co-founded Fucare (Shanghai) Health Techn
ology Co.,



Course Agenda


  1. Overview of Industry Regulatory Requirements
  2. Opportunities and Challenges of Industrial Digital Transformation
  3. Management Scope Covered by Enterprise Digitalization
  4. Methodologies, Implementation Roadmaps and Real-World Cases for Enterprise Digitalization

Registration Information


Time: 19:30 – 21:00, May 7
Keynote Topic: Regulation-Driven Digital Governance and Empowerment System Construction for Pharmaceutical Enterprises
Scan the QR code to reserve your live stream access


Friendly Reminders


  1. Participants who submit complete and authentic registration information will receive priority invitations to join the live stream interactive exchange group of this series.
  2. Three participants with high-quality questions in each session will win a China Red down vest (random size) and a customized tote bag for Young Pharmaceutical Professionals respectively, and get the chance to join live video interaction. Don’t miss this great opportunity — sign up and prepare your questions!